Ascentage Pharma's Presentation at ASH 2025
Ascentage Pharma Group International Inc. (NASDAQ: AAPG) is gearing up to share groundbreaking results from various clinical studies involving its innovative drug, olverembatinib. The upcoming 67th American Society of Hematology (ASH) Annual Meeting, scheduled for December 6-9, 2025, will be the stage for this revelation. This marks a significant achievement, as it's the eighth consecutive year that clinical data on olverembatinib has been highlighted at this prestigious conference.
Significant Studies of Olverembatinib
Ascentage Pharma's olverembatinib has made waves as the first third-generation BCR-ABL inhibitor approved in China, currently commercialized in partnership with Innovent Biologics. The ASH Annual Meeting will feature the inaugural dataset from the global Phase III POLARIS-1 study of olverembatinib combined with low-intensity chemotherapy, specifically targeting patients newly diagnosed with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Alongside this, four-year follow-up data from a Phase II study in patients with chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKIs) will also be presented.
The Importance of ASH Annual Meeting
The ASH Annual Meeting is a pivotal event for hematology professionals as well as researchers. It serves as a platform for the latest scientific advancements in the treatment and understanding of hematologic diseases. This year’s hybrid format will allow global participation, further amplifying the importance of the research being shared.
Insights from Dr. Yifan Zhai
Dr. Yifan Zhai, Chief Medical Officer at Ascentage Pharma, expressed his excitement about the recognition olverembatinib has received within the international hematology community. He noted the importance of continuous innovation in clinical development, mentioning that several significant studies featuring key drug candidates from the company are set to be showcased. Dr. Zhai anticipates sharing in-depth data that could potentially alter treatment paradigms for patients.
Overview of ASH 2025 Presentations
The presentations regarding Ascentage Pharma's drug candidates will provide attendees with critical insights into the clinical efficacy and safety profiles of their innovations. Here’s a snapshot:
Olverembatinib Studies
The studies encompassing olverembatinib will cover various aspects:
- POLARIS-1 Study: Focusing on the safety and efficacy in newly diagnosed Ph+ ALL patients.
- Chronic Myeloid Leukemia: Results measuring outcomes in patients resistant to TKIs, presenting notable progression-free survival metrics.
Long-Term Patient Outcomes
The insights gathered from these studies will not only emphasize the immediate outcomes but also how olverembatinib impacts long-term patient health and treatment resistance.
About Ascentage Pharma
Ascentage Pharma is at the forefront of developing therapies aimed at addressing significant unmet medical needs in oncology. Their robust pipeline includes various innovative therapies targeting key pathways involved in cancer. Among these, olverembatinib stands out as the company's lead asset, showing great promise in treating multiple forms of leukemia. The commitment to advancing treatment options will continue to be a driving force for Ascentage Pharma as they lead in the biopharmaceutical field.
Contact Information
For more information about their advancements and presentations, Ascentage Pharma’s Investor Relations team, led by Hogan Wan, can be contacted at Hogan.Wan@ascentage.com. Media inquiries can be directed to Stephanie Carrington at AscentageIR@icrhealthcare.com.
Frequently Asked Questions
What is Ascentage Pharma's key drug candidate?
The key drug candidate from Ascentage Pharma is olverembatinib, used primarily for treating blood cancers.
When will the ASH Annual Meeting take place?
The ASH Annual Meeting is scheduled for December 6-9, 2025.
What studies will be presented at ASH 2025?
Studies on olverembatinib combined with chemotherapy for Ph+ ALL and tracking outcomes in TK-resistant CML patients will be presented.
Who is the Chief Medical Officer of Ascentage Pharma?
Dr. Yifan Zhai is the Chief Medical Officer of Ascentage Pharma.
Where can I get updates on Ascentage Pharma’s research?
Updates are available through their Investor Relations team and their official website.
